Biopharma Takes on Deadly Brain Cancer After Decades of Failure

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics and others are targeting the often-fatal brain tumor.

Scroll to Top